T he purine nucleoside adenosine is an intermediate product of adenine nucleotide metabolism. Adenosine serves as a "retaliatory metabolite" in situations where oxygen supply is decreased or energy consumption is increased. Under these conditions, adenosine is released into the extracellular space and signals to restore the balance between energy supply and demand. Four extracellular G proteincoupled receptors, namely, A 1 , A 2A , A 2B , and A 3 , mediate adenosine actions. A 2B receptors have a lower affinity compared with other subtypes and require micromolar concentrations of adenosine for their stimulation. 1 Such high levels of extracellular adenosine can be reached during hypoxia, ischemia, inflammation, and injury. 2 The low affinity of A 2B receptors suggests that they are primarily engaged under these pathophysiologic conditions. A 2B receptors regulate various pathological processes, including mast cell activation, 3 vasodilation, 4 inhibition of cardiac fibroblast 5 and vascular smooth muscle growth, 6 stimulation of endothelial cell (EC) growth, 7 and angiogenesis. 8 -10 Stimulation of angiogenesis appears to be an important function of A 2B receptors. We have previously shown that A 2B receptors upregulate the production of angiogenic factors in human mast cells, retinal ECs, and human microvascular endothelial cells (HMEC-1s) under normoxic conditions. 8 -10 Tissue hypoxia is a powerful stimulus for the expression of genes associated with angiogenesis and, as mentioned previously, it is during hypoxia that adenosine levels increase to concentrations that engage A 2B receptors. Therefore, we tested the hypothesis that hypoxia would also modulate expression of adenosine receptor subtypes toward an "angiogenic" A 2B phenotype.
Methods

Cell Culture and Treatment Conditions
Human umbilical vein endothelial cells (HUVECs) were purchased from Cambrex Bio Science (Walkersville, Md), HMEC-1s were provided by Dr D.E. Vaughan (Vanderbilt University, Nashville, Tenn), and normal human bronchial smooth muscle cells (BSMCs) were obtained from Clonetics (San Diego, Calif). Cells were maintained as described previously. 9, 11 Before each experiment, the growing medium was replaced with one containing 1 U/mL adenosine deaminase. Confluent monolayer cultures were exposed to hypoxia in an incubation chamber (BillupsRothenberg) flushed with a 5% CO 2 /95% N 2 gas mixture until the oxygen concentration inside the chamber reached 4.6%. The hypoxic chamber was then sealed and placed in a 37°C cell culture incubator for the indicated time.
Chemicals
5Ј-N-ethylcarboxamidoadenosine (NECA) and 2-p-(2-carboxyethyl)phenethylamino-NECA (CGS21680) were purchased from Research Biochemicals, Inc. CVT-6694 was made at CV Therapeutics (Palo Alto, Calif).
Gene Expression Assay and Real-Time RT-PCR
A human adenosine receptor gene-expression array was customdesigned by Super Array (Bethesda, Mass). The assay and real-time RT-PCR were performed as previously described. 9 Measurement of cAMP cAMP concentrations were determined as previously described. 12 
Determination of VEGF Levels
HUVECs were lysed with phosphate-buffered saline containing 1% NP40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, and a 0.01% protease inhibitor cocktail (Roche). After being passed through a 23-gauge needle, cell debris was pelleted by centrifugation, and vascular endothelial growth factor-A (VEGF) was measured in the supernatant by using an ELISA kit (PeproTech). The concentration of VEGF in the cell media of BSMCs was determined with an ELISA kit (Biosource).
Transfections and Luciferase Reporter Assay
HMEC-1 cells were transfected as previously described. 9 p11w, a firefly luciferase reporter plasmid, comprising the 5Ј-flanking Ϫ985 to Ϫ939 base pairs of the human VEGF gene that include a hypoxia-inducible factor-1 (HIF-1)-binding site, and p11m, the mutated version of p11w containing a nonfunctional HIF-1-binding site, 13 were obtained from the American Type Culture Collection (Manassas, Va). Eighteen hours after transfection, the cells were incubated under hypoxic or normoxic conditions for 12 hours, and reporter activity was measured as previously described. 9 Extended method details can be found in an online supplement available at http://www.hypertensionaha.org.
Results
Effect of Hypoxia on mRNA Expression of Adenosine Receptor Subtypes in HUVECs
Gene-expression array showed that HUVECs incubated under normoxic conditions preferentially express A 2A receptor mRNA (Figure 1 ): the levels of A 2A and A 2B receptors were 1.56Ϯ0.3: and 0.08Ϯ0.01% of ␤-actin, respectively, and no mRNA encoding the A 1 or A 3 receptor was detected. In HUVECs exposed to hypoxia, A 2A receptor mRNA expression was decreased from 1.56Ϯ0.3 (normoxia) to 0.51Ϯ0.12 (1-hour hypoxia) and to 0.16Ϯ0.01% (3-hour hypoxia) of ␤-actin expression. In contrast, A 2B receptor mRNA was increased from 0.08Ϯ0.01 (normoxia) to 0.30Ϯ0.01 (1-hour hypoxia) and to 0.27Ϯ0.05% (3-hour hypoxia). The ratio of mRNA expression of A 2B to A 2A changed from a predominance of A 2A (0.05:1 under normoxia) to a predominance of A 2B (1.6:1, 3-hour hypoxia).
Effect of Hypoxia on Functional Expression of Adenosine Receptors in HUVECs
Activation of A 2A and A 2B adenosine receptors stimulates adenylate cyclase and thus, we used the accumulation of cAMP as a measure of functional phenotypes. Our results confirmed that in normoxic HUVECs, the A 2A receptor is the functional, predominant adenosine receptor ( Figure 2A ). The A 2A -selective agonist CGS21680 activated adenylate cyclase with an EC 50 of 849 nmol/L. The nonselective agonist NECA had a potency (EC 50 of 948 nmol/L) and efficacy similar to that of CGS21680. This pharmacological profile is consistent with the predominant expression of A 2A adenosine receptors. 14 In contrast, in hypoxic HUVECs (3-hour hypoxia), NECA stimulated the accumulation of cAMP with an EC 50 of 1.4 mol/L, whereas CGS21680 was virtually ineffective ( Figure 2B ). This pharmacological profile is consistent with the functional predominance of A 2B receptors. 12, 15 
Effect of Hypoxia on Regulation of VEGF by Adenosine in HUVECs
NECA, 100 mol/L, had no effect on the production of VEGF protein in HUVECs incubated for 3 hours under normoxic conditions (Figure 3 ), in agreement with our previous studies. 9 Under hypoxic conditions, however, NECA increased VEGF protein levels in HUVECs from 9.5Ϯ1.0 to 14.2Ϯ1.2 pg/mL (PϽ0.05).
Effect of Hypoxia on A 2B Receptor mRNA Expression and Regulation of VEGF by Adenosine in SMCs
We used the human SMC line BSMCs as a model of a nonvascular cell type expressing higher levels of VEGF because we previously demonstrated the presence of A 2B receptors in these cells 11 and the lack of effect of adenosine on VEGF secretion under normoxic conditions. Under normoxic conditions, these cells preferentially express A 2B receptors (0.42Ϯ0.04% of ␤-actin, Figure 4 ). Lower levels of A 1 and A 2A receptors were also detected (0.0023Ϯ0.0003 and 0.0097Ϯ0.002% of ␤-actin, respectively), whereas transcripts for A 3 receptors were below detection levels. Incubation of BSMCs under hypoxic conditions for 1 hour increased A 2B receptor transcript levels by 2.4Ϯ0.3-fold (from 0.42Ϯ0.04% to 1.00Ϯ0.13% of ␤-actin, PϽ0.05) but had no significant effect on the expression of A 1 and A 2A receptors (0.004Ϯ0.0006% and 0.0087Ϯ0.0003% of ␤-actin, respectively).
As shown in Figure 5 , NECA (10 mol/L) had no effect on VEGF release in normoxia but increased VEGF release by 2.5Ϯ0.2-fold in hypoxia. The selective A 2B antagonist CVT-6694 11 (1 mol/L) attenuated the effect of NECA by 64Ϯ21%, indicating the involvement of A 2B receptors.
Role of HIF-1 in Regulation of VEGF Transcription by Hypoxia and Adenosine
HIF-1 is a transcription factor that mediates the effects of hypoxia on VEGF expression by binding to the hypoxiaresponse element of the VEGF promoter. 13 We have previously shown that NECA, acting via A 2B receptors, stimulates the VEGF promoter in HMEC-1s. 9 To examine whether NECA interacts with the HIF-1 pathway to upregulate VEGF transcription, we used 2 previously described luciferase reporters. The p11w reporter is regulated by a fragment of the VEGF promoter that includes an HIF-1-binding site. The p11m reporter is identical except for a 3-bp mutation that prevents HIF-1 binding. 13 We coexpressed these reporters with A 2B receptors to minimize the variability in expression levels of A 2B receptors because of potential effects of hypoxia 
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on native adenosine receptors. 16 As shown in Figure 6A , 10 mol/L NECA increased luciferase activity of the p11w reporter by 2.3Ϯ0.03-fold in HMEC-1s incubated under normoxic conditions for 12 hours. Incubation of cells under hypoxic conditions for 12 hours resulted in a 2.2Ϯ0.3-fold and 4.1Ϯ0.1-fold increase in p11w reporter activity in the absence and presence of NECA, respectively. NECA also stimulated activity of the p11m reporter by 2.3Ϯ0.04-fold and 2.0Ϯ0.27-fold under normoxic and hypoxic conditions, respectively, but hypoxia itself had no effect ( Figure 6B ). These results suggest that in contrast to hypoxia, adenosineinduced VEGF upregulation does not require the HIF-1 pathway.
Discussion
Hypoxia is a feature of many pathophysiologic conditions, including ischemia, inflammation, and tumor growth. Cell hypoxia is a potent stimulus for adenosine release. The physiologic importance of adenosine, therefore, is more relevant during hypoxic than normoxic conditions. Mammalian cells respond to hypoxia by significant genetic reprogramming with selective gene induction and downregulation. Our data show that hypoxia produces dramatic changes in the expression of adenosine receptor subtypes in HUVECs. These cells normally express both A 2A and A 2B receptors, but the A 2A receptor predominates in terms of both mRNA expression and functional coupling. 9 Hypoxia downregulated the expression of high-affinity A 2A receptors, but at the same time it increased expression of low-affinity A 2B receptors. Hypoxia also altered responses to adenosine agonists, indicating that changes in mRNA expression led to changes in expression of functional receptors. The nonselective A 2 agonist NECA stimulated adenylate cyclase in hypoxic HUVECs, whereas the selective A 2A agonist CGS21680 was no longer able to do so, indicating that A 2B receptors became functionally predominant in HUVECs after hypoxic treatment.
It should be noted, however, that hypoxia does not always downregulate A 2A receptors. It has been reported that hypoxia increased expression of A 2A receptors in rat PC12 pheochromocytoma cells. 17 It is possible, therefore, that the effects of hypoxia on the expression of A 2A adenosine receptors can be cell-and tissue-specific.
In contrast to downregulating high-affinity A 2A receptors, hypoxia increased mRNA expression of low-affinity A 2B receptors in HUVECs. These results agree with our previous data, which showed that simulation of hypoxia by cobalt ions upregulated the expression of A 2B receptors in U87MG cells. 18 Studies from other laboratories have also shown an upregulation of adenosine A 2B receptors by hypoxia. 16, 19 Of interest, hypoxia not only upregulates A 2B receptors but also increases the levels of endogenous ligand by enhancing hydrolysis of ATP to adenosine through upregulation of surface apyrase (CD39) and 5Ј-nucleotidase (CD73). 16 Therefore, the functional importance of the low-affinity A 2B subtype is probably more relevant under hypoxic conditions, when concentrations of extracellular adenosine are increased. The differential upregulation of adenosine receptors that we report here may provide a positive-feedback mechanism for the engagement of A 2B receptors during hypoxia. The observation that adenosine induced upregulation of VEGF protein levels only after treatment with hypoxia, an effect that was absent in HUVECs maintained under normoxic conditions, indicates that hypoxia-induced modulation of adenosine receptors was functionally important. A switch from expression of mostly A 2A receptors to predominantly the A 2B phenotype could be beneficial if it can promote cell and tissue survival, or it may be detrimental if A 2B receptors participate in inflammatory processes or pathologic angiogenesis. In the cardiovascular system, an upregulation of A 2B receptors in cardiac fibroblasts and SMCs may prevent cardiac remodeling associated with hypertension, myocardial infarction, and myocardial reperfusion injury after ischemia 5, 6 while promoting EC growth and angiogenesis. 7, 9 Although adenosine has long been known to promote angiogenesis, 20 only recently have attempts been made to identify adenosine receptor subtypes that mediate proangiogenic responses. A 2A adenosine receptors can have proangiogenic or antiangiogenic actions depending on the cell type studied. For example, adenosine blunts hypoxia-induced VEGF production in rat pheochromocytoma PC12 cells, a cell line that predominantly expresses A 2A adenosine receptors. Interestingly, selective antagonism of A 2A receptors resulted in increased basal levels of VEGF mRNA in these cells, 21 possibly by unmasking the "angiogenic" effects of A 2B receptors. In contrast, A 2A agonists act synergistically with endotoxin to upregulate VEGF in murine macrophages 22 but had no effect on their own. By comparison, A 2B receptors directly stimulate VEGF production in human retinal ECs, 8 HMEC-1 cells, 9 and human mast cells, 10 even under normoxic conditions. In this study, we have demonstrated that adenosine A 2B receptors stimulated VEGF production only after exposure to hypoxia in 2 different cell types. This gain of function occurs in parallel with the upregulation of A 2B receptors. We have not explored whether enhanced coupling to pathways associated with the regulation of VEGF expression also contributes to this phenomenon.
HIF-1 is a major transcription factor regulating expression of many genes in response to hypoxia, including VEGF. 23 It should be noted that regulation of VEGF transcription is complex and can also be regulated by HIF-1-independent pathways. 24, 25 Indeed, the current study shows that adenosine can regulate VEGF expression independently of HIF-1.
Depending on the cell type studied, adenosine has been shown to upregulate VEGF under normoxic or hypoxic conditions. Some studies have suggested that this effect is more important in normoxia. 26 Others have shown that the effects of hypoxia and adenosine are additive. 27 Our results in HUVECs show that even in cells lacking regulation by adenosine of VEGF under normoxic conditions, adenosine can upregulate VEGF under hypoxic conditions. Even though HUVECs produce relatively small quantities of VEGF in response to hypoxia or to A 2B receptor stimulation, it is possible that modulation of VEGF release through these mechanisms provides an autocrine pathway regulating EC growth. However, ECs are generally not considered a major source of VEGF. Cells located outside the vasculature are thought to release greater amounts of VEGF, establishing a gradient that recruits new blood vessel formation toward the hypoxic focus. Therefore, we extended our studies to BSMCs, a human SMC that expresses greater levels of VEGF compared with HUVECs, both at baseline and during hypoxia. We confirmed that hypoxia increased A 2B receptor expression and that activation of these receptors further increased VEGF release. Thus, A 2B receptors can participate in autocrine and paracrine regulation of EC growth, particularly during hypoxia. It should be noted that our studies were limited to in vitro models of cell function. Additional studies will be required to define the in vivo relevance of these findings. Similarly, it remains to be determined whether hypoxia modulates other functions of adenosine A 2B receptors. For example, both A 2A and A 2B receptors play an important role in the regulation of vascular tone, and it would be interesting to assess whether hypoxia-induced changes in the relative expression of adenosine receptor subtypes translates into changes in the sensitivity of vascular tone to adenosine.
Perspectives
In most cells, both high-affinity A 2A and low-affinity A 2B adenosine receptors are expressed, but only one is functionally predominant. Even though both receptor subtypes are coupled to adenylate cyclase, other signaling pathways are differentially activated by these receptors. We found that hypoxia modulates expression of adenosine receptors in ECs and SMCs toward the low-affinity "proangiogenic" A 2B adenosine receptor subtype. We propose that during pathophysiologic conditions accompanied by hypoxia, A 2B receptors, otherwise "silent," become the predominant adenosine receptor subtype and can be engaged in activation of compensatory mechanisms.
